Crossmark

Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor β

Crossref DOI link: https://doi.org/10.1186/s41181-023-00210-6

Published Online: 2023-09-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wegrzyniak, Olivia https://orcid.org/0000-0001-9636-0390
Zhang, Bo

Rokka, Johanna

Rosestedt, Maria

Mitran, Bogdan

Cheung, Pierre

Puuvuori, Emmi

Ingvast, Sofie

Persson, Jonas

Nordström, Helena

Löfblom, John

Pontén, Fredrik

Frejd, Fredrik Y.

Korsgren, Olle

Eriksson, Jonas

Eriksson, Olof
Funding

Funding for this research was provided by:

European Foundation for the Study of Diabetes

Magnus Bergvalls Stiftelse

Vetenskapsrådet

Barndiabetesfonden

Diabetesfonden

Insamlingsstiftelsen Diabetes Wellness Network Sverige

Science for Life Laboratory

Uppsala University
License Information

Text and Data Mining valid from 2023-09-21

Version of Record valid from 2023-09-21
More Information

Article History

Received: 27 July 2023

Accepted: 4 September 2023

First Online: 21 September 2023

Declarations

:

: Animal care was provided according to the local institutional (“Uppsala University guidelines on animal experimentation”, UFV 2007/724), national, and European Union animal care rules and regulations and conformed to the ARRIVE guidelines. All study protocols involving animal experimentation were approved by the Animal Ethics Committee of the Swedish Animal Welfare Agency. The use of human biopsies was approved by the Swedish Ethical Review Authority (2019–02790).

: Not applicable.

: Bogdan Mitran and Olof Eriksson are employees of Antaros Medical AB. Fredrik Frejd is an employee of Affibody AB. Olle Korsgren and Olof Eriksson are shareholders of Antaros Tracer AB. Otherwise, the authors have nothing to disclose.

Document is current

Any future updates will be listed below